drugset / Trial / NCT04207918
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II clinical study is designed to evaluate the 1 year local tumor control rates after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy with nimotuzumab combined with S-1 in local advanced esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.
Timeline
- Start
- 2019-11-14
- Primary completion
- 2022-12-30
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |
| Subject | S-1 | Small molecule | 40 mg/m2 | Oral |
| Subject | S-1 | Small molecule | 60 mg/m2 | Oral |